Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

42 results about "Activin receptor" patented technology

An Activin receptor is a receptor which binds activin.

Novel activin receptor and uses thereof

The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.
Owner:AMGEN INC

Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof

The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Owner:AMGEN INC

Medicament and method for treating renal disease

A medicament for treating a renal disease, comprising a therapeutically effective amount of an activin inhibitor as an active ingredient. Also, a method for treating a renal disease, comprising administering a therapeutically effective amount of an activin inhibitor to a patient suffering from renal disease is disclosed. The activin inhibitor may be follistatin, an anti-activin antibody, an inhibitor to activin receptor or an anti-activin receptor antibody, an inhibitor to signal transduction relating to activin receptor, an activin production inhibitor in kidney, and the like.
Owner:AJINOMOTO CO INC

Variant activin receptor polypeptides and uses thereof

The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Owner:AMGEN INC

Variant activin receptor polypeptides and uses thereof

ActiveUS20120328595A1Size of tumor massOrganic active ingredientsHydrolasesDiseaseMyostatin
The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Owner:AMGEN INC

Variant activin receptor polypeptides

The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Owner:AMGEN INC

Method for manufacturing pancreatic-hormone-producing cells

The present invention provides a method of more efficiently producing pancreas cells, particularly pancreatic hormone-producing cells, a method of stably producing pancreas cells in a large amount by more efficiently inducing differentiation of stem cells into pancreas cells, a medicament containing a pancreas cells and a screening method using the cells.A method of producing pancreatic hormone-producing cells, including subjecting stem cells to the following steps (1)-(4):(1) a step of cultivating stem cells in a medium containing an activator of activin receptor-like kinase-4,7 and a GSK3 inhibitor(2) a step of cultivating the cells obtained in the aforementioned step (1) in a medium containing an activator of activin receptor-like kinase-4,7(3) a step of cultivating the cells obtained in the aforementioned step (2) in a medium containing any one or more kinds selected from the group consisting of (a) retinoic acid receptor agonists, (b) at least one kind selected from the group consisting of inhibitors of AMP-activated protein kinase and / or activin receptor-like kinase-2,3,6, and BMP antagonists, and (c) inhibitors of activin receptor-like kinase-4,5,7(4) a step of cultivating the cells obtained in the aforementioned step (3).
Owner:TAKEDA PHARMA CO LTD

Application of activin receptor-interacting protein 2 (ARIP2) gene to preparation of medicament

The invention provides application of an activin receptor-interacting protein 2 (ARIP2) gene to preparation of a medicament, relating to the field of liver disease gene therapy medicaments. The application of the ARIP2 gene as a gene therapy medicament for treating liver diseases is characterized in that: a eukaryotic cell expression vector of a recombinant ARIP2 gene is transfected with liver cells, and ARIP2 proteins expressed by the ARIP2 gene in the liver cells can be used for maintaining liver cell survival and reducing inflammatory mediators and extracellular matrixes, so that the regeneration of liver parenchyma cells is facilitated, and liver inflammation and fibration are suppressed. The ARIP2 gene can be used for treating acute liver diseases and chronic liver diseases, including liver diseases such as hepatofibrosis, hepatocirrhosis and the like.
Owner:柳忠辉

Myostatin, activin or activin receptor antagonists for use in treating obesity and related conditions

The present invention relates to myostatin or activin antagonists or receptor antagonists for use in improving body composition, e.g., for the treatment of central adiposity, obesity or overweight condition and related comorbidities. The present invention also relates to myostatin or activin antagonists or receptor antagonists for the treatment of type II diabetes by improving glycemic control, in particular by increasing insulin sensitivity.
Owner:NOVARTIS AG

Activin receptor type iia variants and methods of use thereof

The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, facture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.
Owner:KEROS THERAPEUTICS INC

Activin receptor type iia variants and methods of use thereof

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.
Owner:KEROS THERAPEUTICS INC

CANINE iPS CELLS AND METHOD OF PRODUCING SAME

InactiveUS20110033936A1Stable productionEffectively utilizableGenetically modified cellsCell culture active agentsMitogen-Activated Protein Kinase Kinase InhibitorA-DNA
Provided are a method of producing canine iPS cells, comprising (a) the step of bringing into contact with each other a canine somatic cell and a nuclear reprogramming factor, and (b) the step of culturing the cell in a medium containing at least one substance selected from the group consisting of a mitogen-activated protein kinase kinase inhibitor, an activin receptor-like kinase inhibitor, a glycogen synthase kinase inhibitor, a L-type calcium channel agonist and a DNA methylation inhibitor, and a leukemia inhibitory factor, and canine iPS cells that can be obtained by the method.
Owner:KYOTO UNIV

Compounds and methods for altering activin receptor-like kinase signaling

Described are compounds and methods useful in the promotion of muscle growth, the treatment of muscle loss or insufficient muscle growth, and the treatment of fibrotic conditions.
Owner:ACADEMISCH ZIEKENHUIS BIJ DE UNIV VAN AMSTERDAM ACADEMISCH MEDISCH CENT

Substituted pyridines and methods of use

ActiveUS20210154179A1Limiting adverse side effectMinimal systemic exposurePowder deliveryOrganic chemistryDiseaseKinase
The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products